The primary aim of this trial is to generate a preliminary analysis of this novel therapeutic
approach and laboratory studies for patients with recurrent or refractory CLL. Further, this
pilot trial will demonstrate the feasibility of the translational science methods proposed
for this new collaboration of investigators. The investigators hypothesize that patients with
relapsed CLL are recruitable to this study, that the methods for measuring simvastatin
concentration and target protein translation are feasible, and that the investigators can
efficiently apply the laboratory research methods to patient blood samples before and after
patients have taken the study medication.